[
  {
    "ts": null,
    "headline": "Intel Recovery Still 'Long and Uncertain', Truist Says",
    "summary": "Intel's (INTC) turnaround still faces a long and uncertain road despite delivering mixed Q2 results",
    "url": "https://finnhub.io/api/news?id=723223e6a529ec71b4025c3abd8b2f946ea8539d2959a3e9b79f5b41d9f8b508",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454580,
      "headline": "Intel Recovery Still 'Long and Uncertain', Truist Says",
      "id": 136088778,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Intel's (INTC) turnaround still faces a long and uncertain road despite delivering mixed Q2 results",
      "url": "https://finnhub.io/api/news?id=723223e6a529ec71b4025c3abd8b2f946ea8539d2959a3e9b79f5b41d9f8b508"
    }
  },
  {
    "ts": null,
    "headline": "16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)",
    "summary": "Discover top dividend stocks with the Graham All-Star Value (GASV) strategy.",
    "url": "https://finnhub.io/api/news?id=d9d96cf36545d8f62b9eabe32ffe7fecf985f5e829180b125befa6b353acdd22",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753438877,
      "headline": "16 Ideal 'Safer' Dividend Dogs To Buy From 70 July Graham Value All-Stars (GVAS)",
      "id": 136087899,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "TFC",
      "source": "SeekingAlpha",
      "summary": "Discover top dividend stocks with the Graham All-Star Value (GASV) strategy.",
      "url": "https://finnhub.io/api/news?id=d9d96cf36545d8f62b9eabe32ffe7fecf985f5e829180b125befa6b353acdd22"
    }
  },
  {
    "ts": null,
    "headline": "Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy",
    "summary": "BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. Citing its growing use as a first-line therapy due to […]",
    "url": "https://finnhub.io/api/news?id=a2aa5620ff2545f80533bb46e57fe5a9e41b931b9a54732db93e684c0e946615",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753415274,
      "headline": "Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy",
      "id": 136085092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a $66 price target, spotlighting the promising launch of Attruby for treating ATTR-CM. Citing its growing use as a first-line therapy due to […]",
      "url": "https://finnhub.io/api/news?id=a2aa5620ff2545f80533bb46e57fe5a9e41b931b9a54732db93e684c0e946615"
    }
  }
]